Elizabeth B. Hirsch

2.7k total citations
68 papers, 2.0k citations indexed

About

Elizabeth B. Hirsch is a scholar working on Epidemiology, Molecular Medicine and Pharmacology. According to data from OpenAlex, Elizabeth B. Hirsch has authored 68 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Epidemiology, 26 papers in Molecular Medicine and 23 papers in Pharmacology. Recurrent topics in Elizabeth B. Hirsch's work include Antibiotic Resistance in Bacteria (26 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Urinary Tract Infections Management (14 papers). Elizabeth B. Hirsch is often cited by papers focused on Antibiotic Resistance in Bacteria (26 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Urinary Tract Infections Management (14 papers). Elizabeth B. Hirsch collaborates with scholars based in United States, Australia and Switzerland. Elizabeth B. Hirsch's co-authors include Vincent H. Tam, Monica V. Mahoney, Kimberly R. Ledesma, Paola Zucchi, Mary Motyl, Michael S. Schwartz, Jean-François Hirsch, Dominique Rénier, Graham M. Snyder and James E. Kirby and has published in prestigious journals such as SHILAP Revista de lepidopterología, Academy of Management Journal and PLoS ONE.

In The Last Decade

Elizabeth B. Hirsch

63 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth B. Hirsch United States 21 1.2k 658 578 380 364 68 2.0k
Thomas Tängdén Sweden 22 1.0k 0.9× 550 0.8× 516 0.9× 371 1.0× 218 0.6× 64 1.8k
Alyssa Golden Canada 17 879 0.8× 564 0.9× 609 1.1× 265 0.7× 245 0.7× 44 1.6k
Ayman Noreddin United States 25 1.1k 1.0× 1.0k 1.6× 984 1.7× 315 0.8× 473 1.3× 73 2.9k
S. Bouchillon United States 19 882 0.8× 371 0.6× 623 1.1× 292 0.8× 189 0.5× 34 1.4k
Lütfiye Mülazımoğlu Türkiye 18 1.4k 1.2× 501 0.8× 740 1.3× 488 1.3× 307 0.8× 38 2.5k
Simona Barnini Italy 25 1.1k 0.9× 509 0.8× 641 1.1× 473 1.2× 299 0.8× 59 1.9k
R. Guidos United States 3 746 0.6× 407 0.6× 368 0.6× 483 1.3× 469 1.3× 3 1.9k
Philip Lister United States 24 1.7k 1.4× 853 1.3× 591 1.0× 368 1.0× 985 2.7× 50 2.6k
Giannoula S. Tansarli United States 24 1.4k 1.2× 828 1.3× 1.0k 1.7× 674 1.8× 146 0.4× 50 2.5k
Jared L. Crandon United States 30 1.3k 1.1× 1.4k 2.1× 734 1.3× 439 1.2× 269 0.7× 63 2.1k

Countries citing papers authored by Elizabeth B. Hirsch

Since Specialization
Citations

This map shows the geographic impact of Elizabeth B. Hirsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth B. Hirsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth B. Hirsch more than expected).

Fields of papers citing papers by Elizabeth B. Hirsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth B. Hirsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth B. Hirsch. The network helps show where Elizabeth B. Hirsch may publish in the future.

Co-authorship network of co-authors of Elizabeth B. Hirsch

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth B. Hirsch. A scholar is included among the top collaborators of Elizabeth B. Hirsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth B. Hirsch. Elizabeth B. Hirsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mahoney, Monica V., et al.. (2024). AMRrounds: Achromobacter xylosoxidans susceptibility—so it goes. JAC-Antimicrobial Resistance. 6(5). dlae134–dlae134.
3.
Hirsch, Elizabeth B., et al.. (2023). Predictors of adverse safety events and unscheduled care among an outpatient parenteral antimicrobial therapy (OPAT) patient cohort. Therapeutic Advances in Infectious Disease. 10. 2018414484–2018414484. 6 indexed citations
4.
Vasudeva, Gurneeta, et al.. (2023). Public–Private and Private–Private Collaboration as Pathways for Socially Beneficial Innovation: Evidence from Antimicrobial Drug-Development Tasks. Academy of Management Journal. 67(2). 554–582. 11 indexed citations
5.
Kyono, Yasuhiro, et al.. (2022). The Atypical Antipsychotic Quetiapine Promotes Multiple Antibiotic Resistance in Escherichia coli. Journal of Bacteriology. 204(5). e0010222–e0010222. 10 indexed citations
6.
7.
Abdul‐Mutakabbir, Jacinda C., Elizabeth B. Hirsch, Taison D. Bell, et al.. (2022). A call to action: A need for initiatives that increase equitable access to COVID-19 therapeutics. The Lancet Regional Health - Americas. 11. 100263–100263. 8 indexed citations
8.
O’Donnell, J. Nicholas, Nathaniel J. Rhodes, John S. Esterly, et al.. (2019). Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data. International Journal of Antimicrobial Agents. 55(2). 105849–105849. 4 indexed citations
9.
10.
Olafsdóttir, Lovisa Bjork, Sharon B. Wright, Elizabeth B. Hirsch, et al.. (2017). Adenosine Triphosphate Quantification Correlates Poorly with Microbial Contamination of Duodenoscopes. Infection Control and Hospital Epidemiology. 38(6). 678–684. 22 indexed citations
11.
Chen, Alice P., Kenny Smith, Paola Zucchi, et al.. (2017). Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline. Diagnostic Microbiology and Infectious Disease. 88(4). 365–367. 10 indexed citations
12.
Landersdorfer, Cornelia B., Michelle P. McIntosh, Anton Y. Peleg, et al.. (2016). Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing ofPseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. Journal of Antimicrobial Chemotherapy. 71(8). 2218–2229. 33 indexed citations
13.
Hirsch, Elizabeth B., et al.. (2016). Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections. Therapeutics and Clinical Risk Management. 12. 787–787. 17 indexed citations
14.
Cottreau, Jessica, David Thompson, J. Nicholas O’Donnell, et al.. (2015). Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia. PLoS ONE. 10(11). e0143845–e0143845. 14 indexed citations
15.
Hirsch, Elizabeth B., Kai‐Tai Chang, Paola Zucchi, et al.. (2013). An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. Journal of Infection and Chemotherapy. 20(3). 224–227. 10 indexed citations
16.
Hirsch, Elizabeth B., et al.. (2012). Assessment of Antimicrobial Combinations for Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae. The Journal of Infectious Diseases. 207(5). 786–793. 46 indexed citations
17.
Hirsch, Elizabeth B., et al.. (2011). A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagnostic Microbiology and Infectious Disease. 72(1). 97–102. 20 indexed citations
18.
Hirsch, Elizabeth B. & Vincent H. Tam. (2010). Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomes. Expert Review of Pharmacoeconomics & Outcomes Research. 10(4). 441–451. 339 indexed citations
19.
Hirsch, Elizabeth B. & Vincent H. Tam. (2010). Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. Journal of Antimicrobial Chemotherapy. 65(6). 1119–1125. 395 indexed citations
20.
Sellal, François, et al.. (1991). [Recurrent aseptic meningitis in periodic disease or Mollaret's meningitis?].. PubMed. 147(5). 403–5. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Tängdén Breakdown of academic impact, for papers by Alyssa Golden Breakdown of academic impact, for papers by Ayman Noreddin Breakdown of academic impact, for papers by S. Bouchillon Breakdown of academic impact, for papers by Lütfiye Mülazımoğlu Breakdown of academic impact, for papers by Simona Barnini Breakdown of academic impact, for papers by R. Guidos Breakdown of academic impact, for papers by Philip Lister Breakdown of academic impact, for papers by Giannoula S. Tansarli Breakdown of academic impact, for papers by Jared L. Crandon
Rankless by CCL
2026